GSK's Flonase zooms to top of allergy category after DTC push

GlaxoSmithKline's ($GSK) big advertising push on over-the-counter Flonase appears to be working. The allergy-fighting nasal spray brought in almost $100 million in sales during its first 16 weeks on the market, making it the biggest seller in the allergy field for the period. Report

Suggested Articles

​​​​​​​Baseball and allergy season are in full swing, and Houston Astros pitcher Justin Verlander knows both. He stars in GSK's new seasonal push.

PhRMA’s latest round of drug-cost ads defends a drugmaker favorite—the copay coupon—against new payer programs designed to thwart it.

Researchers plan to tackle issues related to accelerated approval, risk comprehension for new drugs, scientific versus promotional claims and TV ads.